Pharmaceuticals and Medical Devices Council, Cosmetics and Quasi-drugs Subcommittee Meeting to Be Held

SUMMARY

According to a press release from the Ministry of Health, Labour and Welfare, the 'Pharmaceuticals and Medical Devices Council, Cosmetics and Quasi' has been reported. This information provides valuable insight for the management decisions of hospitals, clinics, and medical corporations, reflecting the latest trends in the medical industry.

📝 EDITOR'S NOTE — A Medical M&A Perspective

Trends in the medical industry directly impact the succession and M&A strategies of hospitals, clinics, and medical corporations. Changes in the complex management environment, such as revisions to medical fees, lack of successors, staffing shortages, burden of capital investment, and progress in regional medical plans, are forcing medical institutions to make new management decisions.

As an option for successor issues and changes in the management environment,Third-Party Succession M&Ais increasing in importance year by year. Choosing succession over closure or廃業 (business dissolution) allows for the simultaneous achievement of securing a transfer price, maintaining staff employment, ensuring continuity of patient care, and preserving regional medical services. The framework of M&A support institutions certified by the Small and Medium Enterprise Agency has also been established, and advisory services specializing in the unique licensing, tax, and labor issues of the medical industry have become widespread.

For medical institutions, accurately grasping industry trends and seeking early consultation with experts are key to attracting the best options for management decisions. As an M&A advisory firm specializing in the medical industry, we support medical institutions with free consultations and success-fee-based services.

News Highlights

On May 14, 2026, the Pharmaceuticals and Medical Devices Council, Cosmetics and Quasi-drugs Subcommittee meeting will be held. This subcommittee is expected to deliberate on revisions to the cosmetic standards and matters related to quasi-drugs. Specific agenda items and deliberation details will be announced after the meeting.

Perspective from M&A Medical Editorial Department

The convening of the Pharmaceuticals and Medical Devices Council, Cosmetics and Quasi-drugs Subcommittee meeting not only indicates regulatory trends but can also serve as a potential catalyst for M&A and business succession in the cosmetics and quasi-drugs industry. In particular, the approval of new ingredients or changes in regulations for existing products can directly impact a company’s product portfolio and competitiveness, potentially necessitating business restructuring. For example, it is conceivable that companies aiming to strengthen their R&D capabilities to comply with new regulations or expand product lines tailored to specific market needs might accelerate moves to acquire external technologies and sales channels through M&A. Furthermore, if there are moves towards deregulation, companies may see opportunities for new market entry or business expansion. Such changes are important considerations for small and medium-sized businesses struggling with lack of successors when considering third-party succession.

Points Highlighted by This News

Potential for regulatory changes in the cosmetics and quasi-drugs sector to trigger M&A and business succession
New ingredient approvals and deregulation as factors promoting collaboration and restructuring among companies
M&A as a means to acquire external resources for strengthening R&D capabilities and responding to market needs
The necessity for companies with a lack of successors to formulate business succession strategies based on regulatory trends

Practical Questions Arising from This News

What specific regulatory changes concerning ingredients or products will be discussed at this subcommittee meeting?
What impact might regulatory changes have on our company’s product lineup?
What business strategies should we prepare now in anticipation of future regulatory changes?

If You Feel “Should I Consult Too?”

If your clinic is concerned about the impact of the discussions at this Pharmaceuticals and Medical Devices Council meeting on your business regarding cosmetics or quasi-drugs that you manufacture or sell, please consult M&A Medical. We will propose optimal options tailored to your clinic’s situation from a professional perspective, including business integration as a response to regulatory changes and consideration of business succession schemes for the future.

M&A Medical (CentralMedience Inc.) supports the business succession of medical corporations, hospitals, and clinics on a full success fee basis as an M&A support institution certified by the Small and Medium Enterprise Agency. Consultations are accepted with strict confidentiality. Free consultation here

📌 Source (Primary Information)

Pharmaceuticals and Medical Devices Council, Cosmetics and Quasi

Source: Ministry of Health, Labour and Welfare Press Releases

Please see the original article for details

Regarding trends in medical institutions like this case,

we provide a detailed explanation of the 'Medical Succession Guide'

Read the Complete Guide →